Search
Inhibikase Therapeutics Inc
IKTAdd to Watchlist
2.330USD
+0.160+7.37%
Close 07-23 16:00（ET）Quotes delayed by 15 min
307.64MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Inhibikase Therapeutics Inc is 8.89, ranking 41 out of 386 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 8.00 and a low of 5.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
6.000
Target Price
+169.06%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
495
Total
6
Median
7
Average
Company name
Ratings
Analysts
Inhibikase Therapeutics Inc
IKT
9
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Inhibikase Therapeutics Inc's price target?
Analysts forecast that Inhibikase Therapeutics Inc's price target is USD 8.00, with the highest forecast at USD 8.00 and the lowest forecast at USD 5.00.
How have Inhibikase Therapeutics IncIKT's recent earnings per share performed?
The market expectation was USD -0.10, while Inhibikase Therapeutics IncIKT's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for Inhibikase Therapeutics Inc?
Based on the ratings of Inhibikase Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.